ClinConnect ClinConnect Logo
Search / Trial NCT05112328

The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Nov 4, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of high-dose pancreatic enzyme supplements on critically ill patients who are receiving nutrition through a feeding tube. The researchers want to find out if these supplements can improve patients' nutritional health and overall recovery while they are in a medical or surgical intensive care unit. This is important for patients who may have difficulty digesting food due to their medical conditions.

To participate in the trial, patients must be 19 years or older, currently hospitalized in the intensive care unit at Seoul National University Hospital, and receiving enteral nutrition (feeding through a tube). They should also have specific risk factors for problems with their pancreas, such as severe infections, diabetes, or being on a ventilator. However, patients with certain conditions, like chronic pancreatitis or pancreatic cancer, will not be eligible. If you or a loved one qualifies and decides to take part, you will help researchers understand how these enzyme supplements might help improve the health of critically ill patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults 19 years and older
  • Hospitalized in the surgical/medical intensive care unit of the Seoul National University Hospital
  • Enteral nutrition
  • Patients who consented to this study
  • Patients with risk factors for pancreatic exocrine dysfunction
  • Shock (Norepinephrine)
  • Sepsis (3 rd definition of sepsis)
  • Diabetes
  • Cardiac arrest
  • hyperlactatemia serum lactate \> 2 mmol/L)
  • Mechanical ventilation
  • Continuous renal replacement therapy
  • Exclusion Criteria:
  • chronic pancreatitis
  • unresectable pancreatic cancer
  • History of pancreatectomy
  • Underlying diseases in which the effect of Exocrine pancreatic enzyme administration is difficult to show
  • Inflammatory bowel disease
  • Short bowel syndrome

About Seoul National University Hospital

Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.

Locations

Seoul, , Korea, Republic Of

Seoul, Jongno Gu, Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials